NF2: Mutations and management of disease

Monographs in Human Genetics

Volumn 16, Issue , 2008, Pages 154-166

  Evans, D G R ^a   Wallace, A ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865321042     PISSN: 00770876     EISSN: 16623835     Source Type: Book Series    
DOI: 10.1159/000126601     Document Type: Article

References (50)

1. Evans D G R, Huson S, Donnai D, Neary W, Blair V, Newton V, Harris R: A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-618. (Pubitemid 23007763)
2. Wishart JH: Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J 1822;18:393-397.
3. Cushing H: Tumors of the Nervus Acusticus and the Syndrome of the Cerebello-Pontine Angle. WB Saunders, Philadelphia, 1917.
4. Crowe FW, Schull WJ, Neal JV: A clinical pathological and genetic study of multiple neurofibromatosis. Charles C. Thomas, Springfield Ill, 1956.
5. Seizinger BR, Rouleau GA, Ozelius LG, Ozelius LJ, Faryniarz AG, et al: Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 1987;49:589-594.
6. Rouleau G, Seizinger BR, Ozelius LG, Hobbs WJ, Trofatter JA, et al: Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987;329:246-248. (Pubitemid 17128967)
7. National Institutes of Health Consensus Development Conference Statement on Neurofibromatosis. Arch Neurol 1987;45:575-579.
8. Evans D G R, Huson SM, Donnai D, Neary W, Blair V, et al: A genetic study of type 2 neurofibromatosis in the north west of England and the UK: I. Pre valence, mutation rate, f itness and conf irmation of maternal transmission effect on severity. J Med Genet 1992;29:841-846. (Pubitemid 23035205)
9. Evans D G R, Wallace A, Trueman L, Strachan T: Mosaicism in classical neurofibromatosis type 2: a common mechanism for sporadic disease in tumor prone syndromes? Am J Hum Genet 1998;63:727-736.
10. Seizinger BR, Martuza RL, Gusella JF: Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986;322:644-647. (Pubitemid 16011448)
11. Troffater JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800. (Pubitemid 23093886)
12. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-521. (Pubitemid 23186636)
13. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, et al: Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 1994;55:314-320. (Pubitemid 24233215)
14. Parry DM, MacCollin M, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, et al: Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529-539. (Pubitemid 26269030)
15. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han F-Y, et al: Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-342. (Pubitemid 26266348)
16. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, Mautner: VF Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet 1996;98:534-538
17. [published erratum in Hum Genet 1997;99:292].
18. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF: Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 1998;77:228-233. (Pubitemid 28208444)
19. Evans D G R, Trueman L, Wallace A, Mason S, Strachan T: Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease with truncating mutations. J Med Genet 1998;35:450-455. (Pubitemid 28252151)
20. Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, et al: Genotype-Phenotype Correlations for nervous system tumors in neurofibromatosis 2: A population-based study. Am J Hum Genet 2004;75:231-239. (Pubitemid 38943866)
21. Baser ME, Kuramoto L, Woods RH, Friedman JM, Wallace AJ, et al: The location of constitutional neurofibromatosis 2 (NF2) splice-site mutations is associated with the severity of NF2. J Med Genet 2005;42:540-546. (Pubitemid 40993828)
22. Tsilchorozidou T, Menko, F, Lalloo F, Kidd A, Da Silva R, et al: Constitutional rear rangements of chromosome 22 as a cause of neurofibromatosis type 2. J Med Genet 2004;41:529-534. (Pubitemid 38932113)
23. Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M, Mautner V: Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer 2005;42:384-391. (Pubitemid 40271281)
24. Baser ME: Neurofibromatosis 2 (NF2) mutation databases. http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html
25. Baser ME, and the contributors to the International NF2 Mutation Database: The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 2006;27:297-306.
26. Ahronowitz I, Xin W, Kiely R, Sims K, Maccollin M, Nunes FP: Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 2006;28:1-12. (Pubitemid 46036208)
27. Kluwe L, Mautner VF, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M: Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40:109-114. (Pubitemid 36232815)
28. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, et al: Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003;40:459-463. (Pubitemid 36760665)
29. Evans D G R, Maher ER, Baser ME: Age-related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. J Med Genet 2005;42:630-632. (Pubitemid 41129034)
30. Warren C, James LA, Varley JM, Ramsden RT, Evans DG: Identifying recurrent regions of chromosome loss and gain in 76 vestibular schwannomas using comparative genomic hybridisation (CGH). J Med Genet 2003;40:802-806. (Pubitemid 37485489)
31. Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, et al: Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 2001;6:441-454. (Pubitemid 32487455)
32. Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Lopez-Marin I, et al: CpG island methylation in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Cancer Res 2003;9:5601-5606. (Pubitemid 37499480)
33. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, et al: Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chromosomes Cancer 2005;42:314-319. (Pubitemid 40171195)
34. Evans D G R, Ramsden R, Huson SM, Harris R, Lye R, King TT: Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol 1993;107:401-406. (Pubitemid 23202712)
35. Slattery WH, Brackmann DE, Hitselberger W: Hearing preservation in neurofibromatosis type 2. Am J Otol 1998;19:638-643. (Pubitemid 28409420)
36. Evans D G R, Baser ME, O'Reilly B, Rowe J, Gleeson M, et al: Management of the patient and family with Neurofibromatosis 2: A consensus conference statement. Brit J Neurosurg 2005;19:5-12. (Pubitemid 40824366)
37. Baser ME, Friedman JM, Aeschilman D, Joe H, Wallace AJ, Ramsden RT, Evans D G R: Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002;71:715-723. (Pubitemid 135750506)
38. Sobel RA, Wang Y: Vestibular (acoustic) schwannomas: histological features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 1993;52:106-113. (Pubitemid 23069766)
39. Evans D G R, Newton V, Neary W, Baser ME, Wallace A, et al: Use of MRI and audiological tests in pre-symptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet 2000;37:944-947. (Pubitemid 32002892)
40. Mohyuddin A, Neary WJ, Wallace AJ, Purcell S, Wu C-L, et al: Molecular genetic exclusion of NF2 in young patients diagnosed with a unilateral vestibular schwannoma. J Med Genet 2002;39:315-322. (Pubitemid 34526350)
41. Kluwe L, Friedrich RE, Tatagiba M, Mautner V: Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients, a method based on tumor analysis. Genet Med 2002;4:27-30. (Pubitemid 44698461)
42. Evans D G R, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Wallace A: Mosaicism in NF2 an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including MLPA. J Med Genet 2007;44:424-428. (Pubitemid 47056867)
43. Mautner VF, Lindenau M, Baser ME, Tatagiba M, Haase W, et al: The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurg 1996;38:880-885.
44. King A, Biggs N, Ramsden RT, Wallace A, Gillespie J, Evans D G R: Spinal tumors in neurofibromatosis type 2: is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2005;2:574-579.
45. Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM: Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001;218:434-442. (Pubitemid 32121056)
46. Rowe JG, Radatz M, Walton L, Kemeny AA: Stereotactic radiosurgery for type 2 neurofibromatosis acoustic neuromas: patient selection and tumour size. Stereotact Funct Neurosurg 2002;79:107-116. (Pubitemid 36577068)
47. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA: Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 2003;74:1288-1293.
48. Baser ME, Evans D G R, Jackler RK, Sujansky E, Rubenstein A: Malignant peripheral nerve sheath tumors, radiotherapy, and neurofibromatosis 2. Brit J Cancer 2000;82:998.
49. Friedmann RA, Slattery WH, Brackmann DE, Shwartz MS, Hitselberger WE: Resection of Acoustic Neuroma following Failed Stereotactic Radiosurgical Treatment: Facial nerve outcome. Fourth International Conference on Vestibular Schwannoma and Other CPA Lesions. Conference Proceedings, in Baguley DM, Ramsden RT, Moffat DA (eds): Pubs: Immediate Proceedings, Bungay, Norfolk 2002, pp 29-30.
50. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans D G R: Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759-1765.